<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278898</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-54931</org_study_id>
    <nct_id>NCT04278898</nct_id>
  </id_info>
  <brief_title>Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine</brief_title>
  <official_title>Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: a Single-dose Challenge Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to target the neurobiology of restricted and repetitive behaviors
      in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated
      nutritional supplement that has shown promise for reducing symptom severity in recent
      small-scale trials. The findings from this research will shed light on the mechanisms of
      action underlying the clinical benefits of NAC.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glutamatergic neurometabolites (Glx) measured by proton spectroscopy Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>1 hour after single dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Gamma band amplitude and synchronization measured by electroencephalography</measure>
    <time_frame>1 hour after single dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>N-acetylcysteine Single Dose 2700 mg taken orally</description>
    <arm_group_label>N-acetylcysteine then Placebo</arm_group_label>
    <arm_group_label>Placebo then N-acetylcysteine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged between 3 years and 12 years 11 months,

          -  diagnosis of Autism Spectrum Disorder confirmed with the Autism Diagnostic
             Interview-Revised and the Autism Diagnostic Observation Schedule-2,

          -  at least moderate Restricted and Repetitive Behaviors severity defined by a Children's
             Yale-Brown Obsessive Compulsive Scale for children with autism spectrum disorder score
             â‰¥ 12,

          -  physical development indicative of prepubescence as defined by the criteria for Tanner
             Stage 1,

          -  medically stable,

          -  passes MR safety screening (e.g., no metal in the body).

        Exclusion Criteria:

          -  presence of known genetic abnormalities associated with Autism Spectrum Disorder (e.g.
             Fragile X),

          -  current or life-time diagnosis of severe psychiatric disorder (e.g., schizophrenia),

          -  presence of significant medical problems that would interfere with participation,

          -  the inability of at least one caregiver to speak/read English to a sufficient level to
             complete study requirements and materials,

          -  individuals taking antioxidant agents and glutathione prodrugs, or

          -  the inability/unwillingness to swallow an agent during the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Hegarty, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Hegarty, PhD</last_name>
    <phone>(650) 723-7845</phone>
    <email>hegartyj@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robin Libove, BS</last_name>
    <phone>(650) 736-1235</phone>
    <email>rlibove@stanford.edu</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>John Patrick Hegarty</investigator_full_name>
    <investigator_title>Postdoctoral Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>N-acetylcysteine</keyword>
  <keyword>Restricted and Repetitive Behaviors</keyword>
  <keyword>electroencephalography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-Identified data will be shared with the National Database for Autism Research (NDAR)</ipd_description>
    <ipd_time_frame>The data will be submitted on January 15th and July 15th each year.</ipd_time_frame>
    <ipd_access_criteria>Researchers with access to the National Database for Autism Research (NDAR) will be able to obtain the submitted data.</ipd_access_criteria>
    <ipd_url>https://nda.nih.gov/about.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

